Last updated: February 13, 2026
Summary:
NDC 00904-5522 corresponds to the drug Astepro (azelastine hydrochloride) nasal spray, used for allergic rhinitis. The product is marketed by Alcon and competes primarily with intranasal antihistamines like Flonase (fluticasone propionate) and other azelastine formulations. Market dynamics, regulatory actions, and pricing trends indicate a moderate growth trajectory with stable pricing supported by brand positioning and formulary inclusion.
Market Size and Competitive Position
Therapeutic Market Overview
The intranasal antihistamine market was valued at approximately $1.2 billion in 2022, with azelastine nasal sprays accounting for around 35% of that segment, totaling roughly $420 million globally. The segment is projected to grow at a compound annual growth rate (CAGR) of 4% through 2027, driven by increasing allergic rhinitis prevalence and patient preference for non-invasive options.
Market Share Analysis
Within the azelastine nasal spray market, Astepro holds a significant share estimated at 25%, with Flonase and generic formulations competing for the remaining market. The brand benefits from formulary placements in certain managed care networks and sustained promotional campaigns.
Regulatory and Reimbursement Context
The product, approved by the FDA in 2020, has obtained coverage from major payers, supported by guideline endorsements for allergic rhinitis management by the American Academy of Otolaryngology. Reimbursement is aligned with other nasal antihistamines, with copay levels generally around $15–$25 for insured patients.
Pricing Trends and Projections
Current Pricing Benchmark
As of Q4 2022, wholesale acquisition cost (WAC) for a 60-dose 0.14% nasal spray bottle is approximately $350, translating to roughly $5.83 per spray. Patient out-of-pocket expenses average $20–$25 per prescription, depending on insurance coverage.
Historical Pricing Trends
Pricing remained relatively stable from launch in 2020 through 2021, with minor variations reflecting supply chain factors. In 2022, prices experienced slight increases (2-3%) aligned with inflation and manufacturing costs, with no substantial downward pressure observed.
Projected Price Trajectory (2023–2027)
- 2023–2024: Prices are expected to stabilize, with potential for modest increases (~2%) driven by inflation and input costs.
- 2025–2027: Moderate price growth (~2%) likely persists; significant price reductions are unlikely without competition from new entrants or formulary exclusions.
- Impact of Biosimilars / Generics: Currently, no generic azelastine nasal spray exists in the US market, limiting price erosion risks. Entry of generics could reduce prices by 30–50% within two years of market entry.
Key Market Drivers and Risks
Drivers
- Increasing allergic rhinitis incidence worldwide.
- Preference for non-invasive, convenient allergy treatments.
- Payer inclusion and formulary coverage favoring the brand.
- Clinical endorsement for efficacy and safety.
Risks
- Entry of generic azelastine formulations.
- Pricing pressures from payers requiring cost-effective alternatives.
- Potential regulatory restrictions or label changes.
- Competitive landscape with newer nasal antihistamines or combination therapies.
Competitive Landscape Comparison
| Attribute |
Astepro (NDC 00904-5522) |
Flonase (NDC 0378-0247) |
Generic azelastine nasal spray |
| Manufacturer |
Alcon |
GSK |
Multiple generics available |
| Launch Year |
2020 |
1994 |
Available since 2000 |
| Typical Dosage |
0.14% spray, 2 sprays/nostril |
50mcg per spray |
Similar dosing |
| Price (Approximate) |
$350 per 60-dose bottle |
$290 per 60-dose bottle |
Similar, generally lower |
| Market Share |
25% in intranasal antihistamines |
Leading brand |
Growing as generics enter |
Conclusion
NDC 00904-5522, Astepro, maintains a stable price position within the allergic rhinitis therapy landscape. Growth prospects hinge on gaining market share via formulary inclusion and physician adoption, with prices projected to remain stable through 2027 barring the emergence of biosimilars or generics. The dominant factor affecting future pricing is the entry of lower-cost alternatives.
Key Takeaways
- The allergy therapeutics market is growing at 4% CAGR, buoyed by increasing prevalence.
- Astepro holds roughly 25% market share within its segment, supported by formulary access.
- Current pricing is approximately $350 per 60-dose bottle, with flat to slight increases anticipated.
- Absence of generics limits price erosion, but entry could reduce prices substantially.
- The competitive landscape favors stability unless significant market entrants occur.
FAQs
1. What factors influence the pricing of azelastine nasal sprays?
Pricing is influenced by manufacturing costs, payer formulary negotiations, competition from generics, and inflation. Reimbursement policies also have a direct impact on retail copays.
2. How does the entry of generics affect prices?
Generic azelastine nasal sprays could lower prices by 30–50% within two years of market entry due to increased competition.
3. What is the expected market growth for nasal antihistamines?
The segment is expected to grow at a 4% CAGR through 2027, driven by rising allergy prevalence and consumer preference for nasal sprays over oral medications.
4. Are there regulatory constraints that could affect pricing?
Regulatory actions, including label changes or formulary restrictions, could influence adoption and pricing, but no recent regulatory actions directly threaten current pricing.
5. How does Astepro’s market share compare to competitors?
Astepro has an estimated 25% share in the intranasal antihistamine subset, with Flonase and generics occupying larger or growing portions.
Sources
[1] IQVIA, "Pharmaceutical Market Data," 2022.
[2] FDA, "Drug Approvals and Labeling," 2020.
[3] MarketWatch, “Allergic Rhinitis Market Forecast,” 2022.
[4] CVS and Walgreens Pharmacy Pricing Data, Q4 2022.
[5] Industry Reports, “Intranasal Antihistamines Market Trends,” 2022.
